.: Dierssen, Mara

Selected Publications

Peer-reviewed publications

• 1.Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves R, Dierssen M. Down Syndrome: From Understanding the Neurobiology to Therapy, J. Neurosci. 2010 in press
• 2.Santos M, Summavielle T, Teixeira-Castro A, Silva-Fernandes A, Duarte-Silva S, Marques F, Martins L, Dierssen M, Oliveira P, Sousa N, Maciel P. Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. Neuroscience. 170: 453-67, 2010
• 3.Azkona G, Levanon D, Groner Y, Dierssen M. In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids, in press, 2010 Jul 2. [Epub ahead of print]
• 4.Toiber D, Azkona G, Ben-Ari S, Toran N, Soreq H, Dierssen M. Engineering DYRK1A over-dosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiology of Disease, 40: 348-59, 2010
• 5.Lott IT, Dierssen M. Down Syndrome: Neurological Complications and Cognition. The Lancet Neurology, 9: 623-33, 2010
• 6.Fillat C, Dierssen M, Martinez de Lagran M, Altafaj X. Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. CNS & Neurolog Disord-Drug Targets, 9: 429-38, 2010
• 7.Botella-Lopez A, Cuchillo-Ibañez I, Cotrufo T, Su San Mok, Qiao-Xin Li, Barquero M-S, Dierssen M, Soriano E Saez-Valero J, Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiol Disease 37: 682-91 2010
• 8.Azkona G, Amador-Arjona A, Obradors-Tarrago C, Varea E, Arque G, Pinacho R, Fillat C, de la Luna S, Estivill X, Dierssen M. Characterization of a mouse model overexpressing BACE2 reveals a new role for BACE2. Genes Brain Behav, 9: 160-72, 2010
• 9.Lopes Pereira P, Magnol L, Sahún I, Brault V, Duchon A, Prandini P, Gruart A, Bizot J-C, Chadefaux-Vekemans B, Deutsch S, Trovero F, Delgado-Garcia JM, Antonarakis SE, Dierssen M, Herault Y. A new mouse model for the trisomy of the abcg1-u2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. Human Mol Genet, 18: 4756-69 2009
• 10.Arque G, Martinez de Lagran M, Arbones ML, Dierssen M. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice, Neurobiol Dis, 36: 312-319, 2009
• 11.Dierssen M, Herault, Y, Estivill, X. Aneuploidy: from a physiological mechanism of variance to Down syndrome. Physiol Rev. 89:887-920, 2009
• 12.Gallego X, Murtra P, Zamalloa T, Canals JM, Pineda J, Amador-Arjona A, Maldonado R, Dierssen M. Increased opioid dependence in a mouse model of panic disorder. Frontiers in Neurosci, 3 (60): 1-14 2010
• 13.Heyne A, Kiesselbach C, Sahún I, McDonald J, Gaiffi M, Dierssen M, Wolffgramm J. An animal model of compulsive food taking behaviour. Addict Biol, 14, 373-383 2009
• 14.Amador-Arjona A, Delgado-Morales R, Belda X, Gagliano H, Gallego X, Keck ME, Armario A, Dierssen M. Susceptibility To Stress In Transgenic Mice Overexpressing TrkC, A Model Of Panic Disorder. J Psychiat Res, 44: 157-67, 2010
• 15.Giralt A, Rodrigo T, Martin ED, Gonzalez JR, Ceña V, Dierssen M, Canals JM, Alberch J, Brain Derived Neurotrophic Factor modulates the severity of cognitive alterations induced by mutant huntingtin through changes in phospholipaseCγ activity and glutamate receptor expression. Neuroscience. 18, 158:1234-50, 2009
• 16.Ortiz-Abalia J, Sahún I, Altafaj X, Estivill X, Dierssen M, Fillat C. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in a mouse model of Down syndrome. Am J Hum Genet.83: 479-88. 2008
• 17.Pritchard M, Reeves RH, Dierssen M, Patterson D, Gardiner KJ. Down syndrome and the genes of human chromosome 21: current knowledge and future potentials. Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C. Cytogenet Genome Res. 121: 67-77, 2008
• 18.Cheon, MS., Dierssen M, Kim, SH, Lubec G Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids. 35: 339-43, 2008
• 19.X. Altafaj, J. Ortiz-Abalia, M. Fernandez, M.C. Potier, J. Laffaire, N. Andreu, M. Dierssen, C. Gonzalez-Garcia, V. Ceña, E. Marti and C. Fillat Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis. 32: 377-84, 2008
• 20.Mercader JM, Saus E, Agüera Z, Bayes M, Boni C, Carreras A, Cellini E, de Cid R, Dierssen M, ... Estivill X. Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Hum Mol Genet. 17: 1234-44, 2008
• 21.Mercader JM, Lozano JJ, Sumoy L, Dierssen M, Visa J, Gratacos M, Estivill X. Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model. Physiol Genomics. 12, 35: 341-50, 2008
• 22.Vidal B, ... Dierssen M, Carmeliet P, Degen JL, Dewerchin M, Muñoz-Canoves P.Fibrinogen drives dystrophic muscle fibrosis via a TGF{beta}/alternative macrophage activation pathway. Genes Dev. 22: 1747-52. 2008
• 23.Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics. 120:e1465-71, 2007
• 24.Martinez de Lagran M, Bortolozzi A, Millan O, Gispert JJ, Arbones M, Gonzalez JR, Artigas F, Dierssen M Dopaminergic Deficiency In A Dual-Specificity Tyrosine-Phosphorylated And Regulated Kinase 1A Heterozygous Mice (Dyrk1A+/-) Genes, Brain, Behav 6(6):569-78, 2007
• 25.Dierssen M. Understanding the human brain through mouse models Genes Brain Behav, 6: 1-1, 2007
• 26.Suelves M, ... Dierssen M, Dewerchin M, Carmeliet P, Muñoz-Canoves P uPa deficiency exacerbates muscular dystrophy in mdx mice J Cell Biol. 178:1039-51, 2007
• 27.Sahún I, Delgado-Garcia JM, Amador-Arjona A, Giralt A, Alberch J, Dierssen M Gruart A Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice J. Neurosci. 27: 2253-60. 2007
• 28.Gratacos M., Sahún I., Gallego X., Amador-Arjona A., Estivill X., Dierssen M Candidate genes for panic disorder: insight from human and mouse genetic studies. Genes Brain Behav. 6: 2-23. 2007
• 29.Sahún I, Gallego X, Gratacòs M, Murtra P, Trullas R, Maldonado R, Estivill X, Dierssen M Differential Responses to Anxiogenic Drugs in a Mouse Model of Panic Disorder As Revealed by Fos immunocytochemistry in Specific Areas of the Fear Circuitry. Amino Acids 33: 677-88, 2007
• 30.Dierssen M, Ortiz Abalia J, Arque G, Martinez de Lagran M, Fillat C Pitfalls and hopes in Down syndrome Therapeutic approaches: In the search for evidence-based treatments Behavioural Genetics 36: 454-68, 2006
• 31.Lumbreras M, Baamonde C, Martinez-Cue C, Lubec G, Cairns N, Salles J, Dierssen M, Florez J Brain G protein-dependent signaling pathways in DS and AD AminoAcids 31:449-56, 2006
• 32.Dierssen M, de Lagran MM. DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis. TheScientificWorld Journal 6: 1911-22, 2006
• 33.Dierssen M, Ortiz Abalia J, Arque G, Martinez de Lagran M, Fillat C. Pitfalls and hopes in Down syndrome Therapeutic approaches: In the search for evidence-based treatments. Behavioural Genetics. 36: 454-68, 2006
• 34.Dierssen M, Gratacòs M, Sahún I, Martin M, Armengol L, Gallego X, Amador-Arjona A, Martinez de Lagran M, Murtra P, Pujana MA, Ferrer I, Martinez-Cue C, Florez J, Maldonado R, Fillat C, Estivill X. Overexpression of NTRK3 Increases Anxiety-Like Behavior and Alters Monoaminergic Circuits in Mice. Neurobiol. Disease. 24: 403-18, 2006
• 35.Ferrer I, Barrachina M, Puig B, Martinez de Lagran M, Marti E, Gomez-Isla T, Avila J, Dierssen M Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Dementia with Lewy bodies, Pick disease and related transgenic models. Neurobiol Disease 20(2); 392-400, 2005
• 36.Benavides-Piccione R, Elston GN, Arbones ML, Fotaki V, Estivill X, DeFelipe J, Dierssen M. Alterations in the phenotype of neocortical pyramidal cells in the DYRK1A+/-. Neurobiol Disease 20: 115-122, 2005
• 37.Ayberk Kurt M, Ilker Kafa M, Dierssen M, Davies DC Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of DS. Brain Res 1022: 101-9, 2004
• 38.Fotaki V, Martinez de Lagran M, Estivill X, Arbones M, Dierssen M Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. Behav Neurosci. 118(4): 815-21, 2004
• 39.Benavides-Piccione R, Ballesteros I, Martinez de Lagran M, Elston G, Estivill X, Fillat C, DeFelipe J, Dierssen M On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog. Neurobiol. 74: 111-126, 2004
• 40.Martinez de Lagran M, Altafaj X, Gallego X, Marti E, Estivill X, Fillat C, Dierssen M Motor phenotypic alterations in TgDyrk1A transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Disease 15: 32-142, 2004
• 41.Unterberger U, Lubec G, Dierssen M, Stoltenburg-Didinger G, Farreras JC, Budka H The cerebral cortex in Fetal Down Syndrome J Neural Transm Suppl. 67: 159-163, 2003
• 42.Dierssen M Editor of Special Interest Section: Down syndrome, postgenomic approaches to neurobiological problems. Genes, Brain Behav. 2: 152-156, 2003
• 43.Dierssen M, Benavides-Piccione R, Martinez-Cue C, Estivill X, Florez J, Elston GN, DeFelipe J Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cerebral Cortex, 13 (7): 758-64, 2003
• 44.Marti E, Altafaj X, Dierssen M, ... Estivill X. Dyrk1a expression pattern supports specific roles of this kinase in the adult central nervous system Brain Res, 964: 250-63, 2003
• 45.Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C, Visa J, Soriano E, Estivill X, Arbones ML Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice Mol Cell Biol. 22: 6636-47, 2002
• 46.Fountoulakis M, Juranville JF, Dierssen M, Lubec G Proteomic analysis of the fetal brain Proteomics. 2: 1547-76. 2002
• 47.Martinez-Cue C, Baamonde C, Lumbreras M, Paz J, Davisson MT, Schmidt C, Dierssen M, Florez J Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome Behav Brain Res. 134: 185-200, 2002
• 48.Baamonde C, Lumbreras MA, MartInez-Cue C, Vallina IF, Florez J, Dierssen M Postnatal handling induces long-term modifications in central beta-noradrenergic signalling in rats Stress. 5: 137-47. 2002
• 49.Garcia-Calatayud S, Ruiz JI, Garcia-Fuentes M, Dierssen M, Florez J, Crespo PS Long-chain polyunsaturated fatty acids in rat maternal milk, offspring brain and peripheral tissues in essential fatty acid deficiency Clin. Chem. Lab. Med. 40: 278-84, 2002
• 50.Dierssen M, Fotaki V, Martinez de Lagran M, Gratacòs M, Fillat C, Estivill X Neurobehavioral development of two mouse lines commonly used in transgenic studies. Pharmacol. Biochem. Behav. 73: 19-25, 2002
• 51.Altafaj X, Dierssen M, ... Estivill X Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet. 10: 1915-23. 2001
• 52.Dierssen M, Marti E, Pucharcos C, Fotaki V, Altafaj X, Casas K, Solans A, Arbones ML, Fillat C, Estivill X Functional genomics of Down syndrome: a multidisciplinary approach. J. Neural Transm. 61: 131-48, 2001
• 53.Ruiz de Azua I, Lumbreras MA, Zalduegui A, Baamonde C, Dierssen M, Florez J, Salles J Reduced phospholipase C-beta activity and isoform expression in the cerebellum of TS65Dn mouse: a model of Down syndrome. J. Neurosci. Res. 66: 540-50, 2001
• 54.Chrast R, ... Dierssen M, Pritchard M, Antonarakis SE The mouse brain transcriptome by Serial Analysis of Gene Expression (SAGE): Differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res. 10: 2006-2021. 2000
• 55.Weitzdoerfer R, Dierssen M, Fountoulakis M, Lubec G Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J. Neural Transm. 61: 59-70, 2001
• 56.Weitzdoerfer R, Stolzlechner D, Dierssen M, Ferreres J, Fountoulakis M, Lubec G Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down syndrome brain. J. Neural Transm. 61:347-59, 2001
• 57.Engidawork E, Baiic N, Fountoulakis M, Dierssen M, Greber-Platzer S, Lubec G Beta-amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect. J. Neural Transm. 61: 335-46, 2001
• 58.Yoo BC, Fountoulakis M, Dierssen M, Lubec G Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1. J Neural Transm. 61:321-34, 2001
• 59.Cheon MS, Fountoulakis M, Dierssen M, Ferreres JC, Lubec G Expression profiles of proteins in fetal brain with Down syndrome. J Neural Transm. 61: 311-9, 2001
• 60.Lubec B, Yoo BC, Dierssen M, Balic N, Lubec G Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation. J. Neural Transm. 61: 303-10, 2001
• 61.Cheon MS, Fountoulakis M, Cairns NJ, Dierssen M, Herkner K, Lubec G Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J. Neural Transm. 61: 281-8, 2001
• 62.Kim SH, Dierssen M, Ferreres JC, Fountoulakis M, Lubec G Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains. J. Neural Transm. 61: 273-80, 2001
• 63.Engidawork E, Balic N, Juranville JF, Fountoulakis M, Dierssen M, Lubec G Unaltered expression of Fas (CD95/APO-1), caspase-3, Bcl-2 and annexins in brains of fetal Down syndrome: evidence against increased apoptosis. J. Neural Transm. 61: 149-62, 2001
• 64.Engidawork E, Juranville JF, Fountoulakis M, Dierssen M, Lubec G Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome. J. Neural Transm. 61: 117-30, 2001
• 65.Kim SH, Fountoulakis M, Dierssen M, Lubec G. Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains. J. Neural Transm. 61: 109-16, 2001
• 66.Fuentes JJ, Dierssen M, Pucharcos C, Fillat C, Casas C, Estivill X, Pritchard M Application of Alu-splice PCR on 21 chromosome: DSCR1 and Intersectin. J. Neural Trans. 57: 337-352, 2000
• 67.Chrast R, Scott HS, Papasavvas MP, Rossier C, Antonarakis ES, Barras C, Davisson MT, Schmidt C, Estivill X, Dierssen M, Pritchard M, Antonarakis SE The mouse brain transcriptome by Serial Analysis of Gene Expression (SAGE): Differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res. 10: 2006-2021, 2000
• 68.Kurt MA, Davies DC, Kidd M, Dierssen M, Florez J. Synaptic Deficit in the Temporal Cortex of Partial Trisomy 16 (Ts65Dn). Mice Brain Res. 858: 191-197, 2000
• 69.Baamonde C, Lumbreras M, Martinez-Cue C, Vallina IF, Garcia-Calatayud S, Florez J, Dierssen M Acute effect of postnatal manipulation on central beta-adrenoceptor transmission Stress 3:147-162, 1999
• 70.Martinez-Cue C, Baamonde C, Vallina IF, Dierssen M, Florez J. A murine model for Down syndrome shows reduced responsiveness to pain. Neuroreport 10: 1119-1122, 1999
• 71.Escorihuela RM, Martinez-Cue C, Vallina IF, Baamonde C, Dierssen M, Tobeña A, Florez J, Fernandez-Teruel A Impaired short- and lon-term memory in Ts65Dn mice. Neurosci. Lett. 247: 171-174, 1998
• 72.Insausti AM, Megias M, Crespo D, Cruz-Orive LM, Dierssen M, Vallina IF, Insausti R, Florez J Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci. Lett. 253: 1-4, 1998
• 73.Dierssen M, Vallina IF, Baamonde C, Garcia-Calatayud S, Lumbreras MA, Florez J Alterations of central noradrenergic transmission in Ts65Dn mouse, a genetic model for Down syndrome Brain Res. 16: 33-44, 1997
• 74.Megias M, Verduga R, Dierssen M, Florez J, Insausti R, Crespo D Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice Neuroreport 8: 3475-78, 1997
• 75.Dierssen M, Vallina I, Baamonde C, Lumbreras MA, Martinez-Cue MC, Garcia-Calatayud S, Florez J. Impaired cyclic AMP production in the hippocampus of a Down syndrome murine model. Dev. Brain Res. 95: 122-124. 1996
• 76.Escorihuela RM, Fernandez-Teruel A, Tobeña A, Vivas NM, Marmol F, Badia A, Dierssen M Early environmental enrichment produces long lasting neurchemical changes on ß-adrenoceptor transduction system. Neurobiol. Learn. Mem. 64: 49-57, 1995
• 77.Escorihuela RM, Fernandez-Teruel A, Vallina IF, Baamonde C, Dierssen M, Tobeña A, Florez J A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 199: 143-146, 1995
• 78.Dierssen M, Vivas NM, Màrmol F, Salles J, Badia A. The action of THA on noradrenergic effector systems: its interaction with cholinergic transmission in brain. Neuropharmacology 34: 367-375, 1995
• 79.Aguado F, Badia A, Baños JE, Bosch F, Bozzo C, Camps P, Contreras J, Dierssen M, Escolano C, Görbig D.M, Vivas NM Synthesis and evaluation of tacrine-related compounds for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 29: 205-221, 1994
• 80.Vivas NM, Màrmol, F, Badia A, Dierssen M Differential effects of physostigmine and THA on ß-adrenoceptor transduction system. European J. Mol. Pharmacoly. 245: 9-13, 1993
• 81.Gascon S, Dierssen M, Màrmol F, Vivas NM, Badia A Effects of age on a1-adrenoceptor subtypes in the rat ventricular muscle. J. Pharm. Pharmacol. 45:907-909, 1993
• 82.Ruiz F, Dierssen M, Florez J, Hurle MA. The calcium channel agonist BAY K 8644 induces central respiratory depression in cats, an effect blocked by naloxone. Eur. J. Pharmaco. 240:155-161, 1993
• 83.Ruiz F, Dierssen M, Florez J, Hurle M Potentiation of acute respiratory depression and reversion of tolerance by the calcium antagonist nimodipine in awake rats. Naun-Schmied. Arch. Pharmacol. 348: 633-637. 1993
• 84.Dierssen M, Màrmol F, Vivas NM, Clos V, Badia A Posttrain administration of 9-amino-1,2,3,4-tetrahydroacridine enhances passive avoidance retention and decreases ß-adrenoceptor linked cyclic AMP formation in middle-aged rats. Brain Res. 586: 117-120,1992
• 85.Dierssen M, Màrmol F, Vivas NM, Clos MV, Gascon S, Badia A Acute effects of tetrahydroaminoacridine on ß adrenoceptor linked cyclic AMP accumulation in brain of young and senescent rats. Neurosci. Lett. 132:51-54, 1991
• 86.Dierssen M, Ruiz F, Florez J, Hurle MA Calcium channel modulation by dihydropyridines modifies sufentanil-induced respiratory depression in cats. Eur. J. Pharmacol. 198: 149-155, 1991
• 87.Dierssen M, Florez J, Hurle MA Influence of calcium channel modulation on opiate analgesia and tolerance Naun- Schmied. Arch. Pharmacol. 342: 559-565, 1990
• 88.Dierssen M, Florez J, Hurle MA Lack of interaction between cholecystokinin and opioid systems on the respiratory function. Rev. Esp. Fisiol. 45: 185-190, 1989
• 89.Hurle MA, Dierssen M, Morin-Surun MP, Oceja C, Florez J Respiratory actions induced by cholecystokinin at the brain stem level. Peptides 9: 809-815, 1988
• 90.Hurle MA, Dierssen M, Florez J Mechanism of the respiratory action of pentobarbital at the medullary and pontine levels. Eur. J. Pharmacol. 125: 225-232, 1986

C. Research Support. (Selected Grants in the last 3 years)

• 2009-2011 ERA-NET E-Rare (EU/FIS PS09102673) Targeting Rho-signalling, a new therapeutic avenue in fragile X syndrome (CureFXS). Role: PI- Coordinator
• 2009-2011 Marato TV3 Neregulin/ErbB4 signaling pathways and development of cortical inhibitory circuits: implications for the ethiology of schizophrenia. Role: Investigator
• 2009-2011 Queen Sofia Foundation (FP006/09) Analisis funcional de la interaccion DREAM-DYRK1A en modelos murinos de enfermedad de Alzheimer y sindrome de Down. Role: PI
• 2009-2011 Spanish Ministry of Health (FIS PI082038) Caracterizacion fenotipica de modelos animales para trastornos neuropsiquiatricos relacionados con la conducta compulsiva. Role: PI
• 2008-2009 Spanish Ministry of Education and Science (SAF2007-31093-E) ModF2_Aneuploidy: understanding gene dosage imbalance in human health using genetics, functional genomics and systems biology. Role: PI
• 2007-2010 Spanish Ministry of Education and Science (SAF2007-60827) Papel de las isoformas por procesamiento post-transcripcional alternativo salvaje y con inserto del receptor de neurotrofina 3 (TrkC) en los procesos de memoria y aprendizaje relacionados con la adiccion. Role: PI
• 2007-2010 Marato TV3 Implication of Dyrk1A, a candidate gene for Down syndrome, in Alzheimer's type pathology and characterization of the neuropathological and cognitive effects of cytotoxic protofibrils from peptides derived of natural amyloid proteins in Dyrk1A mouse models. Role: PI
• 2007-2010 Ramon Areces Foundation. Bases moleculares del papel funcional de las isoformas salvaje y con inserto del receptor de neurotrofina 3 (TrkC) en los procesos de memoria y aprendizaje dependientes del circuito cortico-hipocampico. Role: PI
• 2007-2009 Fundacion Jerôme Lejeune. (JMLM/AC/08-044) Novel hypothesis driven therapeutic strategies for the reversion of Down syndrome cognitive phenotypes Role: PI
• 2004-2007 Spanish Ministry of Science and Technology (GEN2003-20651-C06-03) Modelos Murinos para el estudio de la hipotesis trofica del abuso de sustancias: Perfiles de expresion genica. Role: PI
• 2007-2010 European Comission (FP6-2005-LIFESCIHEALTH-6) Phenotypical characterisation of animal models for neuropsychiatric disorders related to compulsive behaviour. Role: PI Workpackage
• 2006-2010 European Comission (FP6-Aneuploidy 037627) AnEUploidy: understanding gene dosage imbalance in human health using genetics, functional genomics and systems biology. Role: PI Workpackage

D. Other publications

• Books, book chapters and special issues:
• 1.Editor: GBB Special issue on Mouse Models of CNS Disease, 2006.
• 2.Dierssen M, et al Genotype-phenotype neural correlates in trisomy 21 In: The Adult with Down Syndrome. A new challenge for society. Edited by Jean A.Rondal, Alberto Rasore-Quartino and Salvatore Soresi. Whurr Publishers, pages 15-30, London. 2004
• 3.Florez J. Dierssen M. Cerebro disminuido: el valor de la emocion y la motivacion. En: "El Cerebro sintiente" Ed. F. Mora. capitulo 6, pp. 135-151. Ariel Neurociencia. Barcelona. 2000
• 4.Martinez-Cue C, Baamonde C, Lumbreras MA, Paz J, Dierssen M, Florez J Modelos animales de sindrome de Down: perspectivas terapeuticas In: La Farmacologia Española del año 2000 Libro Homenaje al Profesor Pedro Sanchez Garcia. Publ. Universidad autonoma de Madrid 2000, p. 223-238.Madrid. 2000
• 5.Dierssen M, et al Modelling Down syndrome in mice. En: Gerlai R, Crusio W eds. Molecular-Genetic Techniques for Brain and Behavior Research, Elsevier. 1999
• 6.Fuentes JJ, Dierssen M, Pucharcos C, Fillat C, Casa C, Estivill X, Pritchard M. Application of Alu-splice PCR on 21 chromosome: DSCR1 and Intersectin. In: The Molecular Biology of Down syndrome brain. Springer Verlag, Viena. 1999
• 7.Dierssen M, Florez J. Farmacos nootropos y neuroprotectores. Farmacologia de las conductas anormales. In: Farmacologia Humana (3 edicion). Ed. J. Florez. Masson-Salvat. 1997
• 8.Florez, J, Escorihuela RM, Baamonde C, Vallina IF, Martimez-Cue C, Lumbreras M, Dierssen M. Modelos animales de sindrome de Down: soluciones e incertidumbres. In: Sindrome de Down: biologia conducta y educacion. Ediciones Masson-Salvat, pp 49-58. 1996
• 9.Escorihuela R, Fernandez-Teruel A, Vallina I, Baamonde C, Lumbreras M, Martinez-Cue C, Dierssen M, Tobeña A, Florez J. Caracterizacion conductual del raton Ts65Dn: un modelo animal de sindrome de Down. In: Sindrome de Down: biologia conducta y educacion. Ediciones Masson-Salvat,pp 77-88. 1996.
• 10. Dierssen M, et al El raton Ts65Dn: neuroquimica y morfologia cerebrales. In: Sindrome de Down: biologia conducta y educacion. Ediciones Masson-Salvat, pp 59-78. 1996.
• 11.Florez J, Troncoso MV, Dierssen M. La investigacion española sobre el sindrome de Down: una vision panoramica. In: Sindrome de Down: biologia conducta y educacion. Ediciones Masson-Salvat, 1-12. 1996.
• 12.Estivill X, ... Dierssen M, Florez J, Pritchard M. Diseccion molecular del cromosoma 21 humano y del sindrome de Down. In: Sindrome de Down: biologia conducta y educacion Ediciones Masson-Salvat, pp 13-24. 1996.
• 13.Book: "Sindrome de Down: biologia conducta y educacion". Ed. J.Florez, M.V. Troncoso, M. Dierssen, Ediciones Masson-Salvat, 1996. 248pp.
• 14.Dierssen M. Farmacodinamia. In: Farmacologia ocular. M. March Pujol y J. E. Baños Diez. Eds. Politex Col.leccio. Area de Biologia i Mineralogia. Ediciones UPC, 25: 45-52, Barcelona. 1994
• 15.Dierssen M. Farmacologia de la acomodacion. In: Farmacologia ocular. M. March Pujol y J. E. Baños Diez Eds. Politex Col.leccio. Area de Biologia i Mineralogia. Ediciones UPC, 25: 169-172, Barcelona. 1994
• 16.Dierssen M, Salles J, Vivas N, Màrmol F, Badia A. Nuevos enfoques en la terapia de reposicion de neurotransmisores en la enfermedad de Alzheimer: influencia de la tacrina sobre el balance de respuesta noradrenergico-colinergico en el SNC. Farmacologia del SNC, 8(4):125-142. 1994
• 17.Salles J, Dierssen M. Neurobiologia del abuso de anfetaminas y sustancias derivadas. In: Psicoestimulantes: cocaina, anfetaminas y xantinas. Avances en Farmacologia de drogodependencias, Eds. J. Meana y F. Barturen. Instituto Deusto de Drogodependencias, Universidad de Deusto. pp: 47-87. 1993.
• 18.Florez J, Dierssen M, Hurle MA. Opiate analgesia and calcium channel modulation by dihydropyridines under acute and tolerant conditions. Progress in Clinical and Biological Research, 328: 461-464. 1990
• 19.Hurle MA, Dierssen M, Ruiz F, Florez J. Influence of calcium channel agonists on the opiate activity at the respiratory centers of cats. New leads in opioid research, Eds. J.M. Van Reed, A.H. Mulder, V.M. Wiegant T.B. Van Wimersma, pp: 344-346. 1990
• 20.Dierssen M, Florez J, Hurle MA. Blockade of calcium channel with nimodipine enhances opiate analgesia in naive and tolerant rats. Advances in the Biosciences, 75: 308-311. 1989
• 21.Florez J, Dierssen M, Hurle MA. Influence of nimodipine on the respiratory effect of sufentanil at the brain-stem level. Advances in the Biosciences, 75: 535-539, 1989.
• 22.Florez J, Dierssen M, Hurle MA. Calcium antagonists: actions in the Central Nervous System. In: Recent advances in pharmacology and therapeutics Eds. M. Velasco, A. Israel, E. Romero, H. Silva, pp: 77-82. 1989. Elsevier Science Publisher B.V. (Biomedical Division)
• 23.Hurle MA, Dierssen M, Morin-Surun MP, Florez J. Respiratory actions of cholecystokinin and its interaction with opioids at the brain-stem level. In: "Control of breathing during sleep and anesthesia", Eds.: W.A. Karczewski, P. Grieb, J. Kulesza y G. Bonsignore. Plenum Press, N. York, 155-158. 1988